MedTrace Logo

XP13512 vs. Placebo in Patients With Restless Legs Syndrome.

NCT00365352 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 325

Last updated 2013-07-22

Study results available
· View outcomes & findings →

Summary

The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

XP13512 600MG

XP13512 600MG ONCE DAILY

DRUG

XP13512 1200MG

XP13512 1200MG ONCE DAILY

DRUG

PLACEBO

PLACEBO ONCE DAILY

Sponsors & Collaborators

  • XenoPort, Inc.

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2007-12-31
Completion
2007-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00365352 on ClinicalTrials.gov